Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $0.70, $0.05 better than the analyst estimate of $0.65. Revenue for the quarter came in at $286 million versus the consensus estimate of $286.21 million.

Charles River Laboratories reaffirmed FY2012 guidance.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.

Earnings